Objectives: To estimate the incremental cost-utility ratio (ICUR) for the use of a continuous infusion pump with integrated monitoring (SAP) compared with the application of multiple daily injections (MDI) in adult (> 15 year-old) patients with type 1 diabetes mellitus (DM1) in Colombia. MethOds: We designed an annual cycle Markov model, with transition probabilities obtained from a systematic review of the literature. Outcomes included in the search were ketoacidosis, severe hypoglycemia, microvascular complications (retinopathy, nephropathy, neuropathy), quality of life (expressed in quality-adjusted life years, QALYs, and obtained from Tufts database), as well as mortality. Other features of the model were: discount rate 3.5% for costs and QALYs, third party payer perspective (only direct medical costs), and a lifespan time horizon (up to 55 years). Threshold used was three times per capita gross domestic product (GDP), equivalent to € 17,547. Costs were estimated in 2014 Colombian pesos (1 euro = 2,660 COP), from base case scenarios (built by expert panels) and official tariff manuals. Univariate and probabilistic sensitivity analysis were performed. Results: For the average patient, continuous infusion pump has a total expected cost of € 199,296, and generates 16.40 QALYs, while multiple daily injections would cost € 104737, and generate 14.48 QALYs (ICER € 49,302 per additional QALY gained). Sensitivity analysis shows that the only critical variable is the annual cost of continuous infusion pump treatment, which would have to be reduced by 40% to reach the cost-utility threshold. cOnclusiOns: Under the assumptions of the model, treatment with continuous infusion pumps would not be cost-effective for the average adult DM1 patient in Colombia. Further analysis would be required, addressed to certain selected subgroups of patients.
Objectives: To evaluate cost-utility of HAL assisted TURB in comparison to TURB with WLC alone in patients with previously diagnosed NIMBC in Poland. MethOds: Analysis was performed in 2014, from a public payer's perspective with a lifetime horizon. "HAL cost-effectiveness model in non-muscle invasive bladder cancer (NIMBC)" by Pharmerit Ltd. was adapted to Polish settings. The model consists of two parts: a short-term decision tree to assess outcomes of TURB and a Markov cohort model developed in order to examine long-term outcomes. Clinical efficacy of HAL was based on a systematic review of randomized clinical trials. Data concerning course of disease and standard of care in Poland were based on available observational studies, expert opinion and guidelines. Difference in utilization of resources between HAL assisted TURB and TURB with WLC alone was estimated on the basis of expert survey. Unit costs of drugs and medical procedures were based on Ministry of Health (MoH) and National Health Fund tariffs. Costs and effects were discounted at rates of 5% and 3.5%, respectively. The cost-effectiveness threshold was set to 119,577 PLN according to MoH requirements. Probabilistic sensitivity analyses (PSA) were conducted to assess the probability that HAL is cost-effective in Polish settings. Results: The difference in health outcomes between HAL assisted TURB and TURB with WLC alone was 0.034 QALY in favor of HAL. HAL assisted TURB was approximately 172 PLN more expensive than TURB with WLC alone. Incremental cost per QALY equaled 4,997 PLN. PSA indicated that HAL was cost-effective with probability of 95.9% and dominant with probability of 44.6%. cOnclusiOns: Use of HAL to assist TURB is cost-effective in Poland when compared with TURB with WLC alone.
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HealtH-eConoMiC analysis of tHe Use of sensor-aUgMenteD PUMP (saP) tHeraPy in tHe netHerlanDs CoMPareD to insUlin PUMP tHeraPy alone (Csii), in tyPe 1 DiaBetiC Patients
Roze S 1 , Duteil E 2 , De Brouwer BF 3 , de Portu S 4 1 HEVA HEOR Sarl, Lyon, France, Lyon, France, 3 Medtronic Trading NL BV, Heerlen, The Netherlands, 4 Medtronic International Sàrl, Tolochenaz, Switzerland Objectives: To assess the cost-effectiveness and to project the clinical benefits of sensor augmented pump (SAP) compared to continuous subcutaneous insulin infusion therapy alone (CSII), in type 1 diabetic patients (T1D), in Netherlands. MethOds: The Core Diabetes Model was used to project the incidence of diabetes-related complications, based on a meta-analysis from Pickup comparing SAP vs CSII. In the Pickup meta-analysis, 70% sensor usage in a population with baseline HbA1c of 8.0% led to a reduction of -0.42% versus -0.10% HbA1c, for SAP and CSII respectively. The simulated population had a mean age of 27 years with a mean diabetes duration of 13 years. The quality of life was adjusted for a reduced fear of hypoglycaemic event in the SAP arm. A discount rate of 4% and 1.5% for respectively economic and clinical outcomes was applied. Several sensitivity analysis were conducted on key parameters. Results: The incremental cost-effectiveness ratio (ICER) was 22,335 € per Quality Adjusted Life Year gained (QALY) based on a societal perspective. The improvement in discounted QALY was 1.768 years in favor of SAP. SAP additional related costs were partially offset by the savings due to the reduction in diabetes long-term complications and lower frequency of SMBG. Reduction in the incidence (%) and delay of onset of diabetes complications (years) were achieved with SAP compared to CSII alone, such as neuropathy (13% 1.3 years), first ulcer (5% 1.19 years) and stroke (4% 0.81 years). The acceptability curve showed that the likelihood to be cost-effective at a willingness to pay of 80,000 € /QALY was 100%. cOnclusiOns: These results indicate that accordingly to commonly accepted threshold SAP compared to CSII alone can be considered as very good value for money in the Dutch setting. Extensive sensitivity analysis on key drivers confirmed the robustness of results.
follow-up this may not always be the most cost-effective alternative. In fact, economic evaluations have shown that incremental cost-effectiveness ratios (ICERs) of CRT-D may be substantially higher than for comparators. A recent study demonstrated that certain biomarkers may in fact reflect the increased susceptibility to SCD in patients with HF and this may further contribute to increase cost-effectiveness of the CRT-D interventions. The objective of this study was to explore the cost-effectiveness of a hypothetical perfect biomarker for risk assessment and subsequent treatment decision in implanting CRT-Ds in heart failure patients who comply with the current clinical guidelines and assess the societal value (headroom) of such test. MethOds: The study uses a decision analytical model. Results: The use of a hypothetical perfect biomarker for implanting CRT-Ds in heart failure patients is a cost-effective healthcare intervention. The headroom (societal willingness to pay multiplied by incremental quality-adjusted life years) available for the hypothetical perfect biomarker ranged from € 1,530 to € 6,120 depending on the willingness to pay threshold. cOnclusiOns: The use of a hypothetical perfect biomarker for implanting CRT-D is cost effective. Substantial cost can be saved by a better identification of patients with high-risk for SCD and for whom implantation of CRT-Ds reduces risks of death. However, further research of risk stratifying biomarkers test accuracy is needed to support and strengthen the results of this modeling study.
PMD89 long-terM Cost-effeCtiveness of transanal irrigation in Patients WitH neUrogeniC BoWel DysfUnCtion WHo Have faileD stanDarD BoWel Care
Emmanuel A 1 , Christensen P 2 , Kumar G 3 , Passananti V 1 , Mealing S 4 , Stoerling ZM 5 , Andersen F 5 , Soerensen J 5 , Kirshblum S 6 1 University College London Hospital, London, UK, 2 Aarhus University Hospital, Aarhus, Denmark, 3 ICON Health Economics, Oxford, UK, 4 ICON Health Economics and Epidemiology, Oxford, UK, 5 Coloplast A/S, Humlebaek, Denmark, 6 Rutgers New Jersey Medical School, Newark, NJ, USA Objectives: To investigate the long-term cost-effectiveness of initiating transanal irrigation* (TAI) as second-line management in patients with neurogenic bowel dysfunction (NBD) who have failed first-line standard bowel care (SBC). MethOds: A deterministic Markov decision model was developed to project the lifetime health economic outcomes, including quality-adjusted life expectancy (QALE), episodes of faecal incontinence (FI), urinary tract infections (UTIs), and stoma surgery when using TAI relative to continuing SBC. Patients could transition from TAI to (a) another round of first-line SBC, (b) third-line surgeries (sacral nerve stimulator, sacral anterior root stimulator, antegrade continence enema) or (c) stoma as the absorbing state. Transition probabilities and QALE estimates were based on real-world data collected at three clinics in UK from 2007-2014, in NBD patients due to spinal cord injury (SCI), multiple sclerosis, spina bifida, and cauda equina syndrome. Transition probabilities for failed SBC patients were collected from 2000-2007 prior to availability of TAI. Projected life-expectancy was based on published SCI population data. One-way sensitivity analyses were applied. Results: The model predicts that a SCI patient diagnosed aged 30, with a life expectancy of 37 years using TAI, will experience a 36.1% reduction in FI, 28.7% reduction in UTIs, a 35.4% reduction in stoma surgery and improvement of 0.40 years of QALE, compared with patients continuing SBC. Lifetime cost-savings of £41,620 per patient was estimated for TAI versus SBC in a SCI patient, primarily due to avoided hospitalizations and stoma surgeries. Incremental cost can differ due to altered life-expectancy (and age of diagnosis) in the patient cohort. One-way sensitivity analyses indicated that the model was most sensitive to variation in utilities on TAI and SBC treatment. cOnclusiOns: TAI is a cost-saving treatment strategy reducing risk of stoma surgery and improving QALE for NBD patients who have failed SBC. *Peristeen (Coloplast A/S).
PMD90 reDUCtion of CoMPliCations anD assoCiateD Costs for tyPe 2 DiaBetiC Patients Using ContinUoUs sUBCUtaneoUs insUlin infUsion in tHe Uk
Roze S 1 , Duteil E 2 , Hallas N 3 , de Portu S 4 1 HEVA HEOR Sarl, Lyon, France, 2 HEVA-HEOR, Lyon, France, 3 Medtronic, watford, UK, 4 Medtronic International Sàrl, Tolochenaz, Switzerland Objectives: To assess the reduction of complications and costs with continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in uncontrolled type 2 diabetic patients (T2D) in the UK. MethOds: The incidence of diabetes-related complications was calculated based on the Core Diabetes Model. The population characteristics, the reduction of HbA1c, and insulin dose were based on the Opt2mise study (Reznik et al., Lancet 2014) (mean age 56 years (SD 9.6); mean diabetes duration 15 years (SD 0.75)). For a baseline HbA1c of 9.0%, the reduction in HbA1c was -1.1 % versus -0.4%, respectively, for CSII vs MDI. Costs were UK-specific and expressed in £2014. Results: The diabetes-related complications were reduced with CSII. At 5 years, the incidence reduction in complications associated with eye diseases, renal diseases, ulcer/amputation and cardiovascular diseases were -24%, -26%, -19% and -10%, respectively, in favour of CSII. This equates to a cost reduction of 12% over 5 years per patient. End stage renal disease was delayed by 1 year, neuropathy by 1.08 years and amputation by 0.87 year, myocardial infarction and stroke by 0.81 and 0.71 year respectively. Insulin dose was reduced for patients on CSII from 122.1 IU to 96.5 IU per day with a cost saving of £2,169 per patient over 5 years. cOnclusiOns: Improvements in HbA1c with a decrease in overall insulin requirements observed with CSII versus MDI, may offer important reductions in diabetes-related complications and associated costs in a UK setting for uncontrolled T2DM patients.
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Cost-Utility analysis of ContinUoUs infUsion PUMP WitH integrateD Monitoring CoMPareD WitH MUltiPle Daily injeCtion treatMent for Patients 15-years or olDer WitH tyPe 1 DiaBetes MellitUs in ColoMBia
Quitian H 1 , Gomez AM 1 , Garcia Peña AA 1 , Arciniegas J 1 , Iragorri N 1 , Mantilla B 1 , Gomez-Restrepo C 1 , Rosselli D 2 spirometry, BDR and FeNO testing. Where diagnostic uncertainty remained, individuals would then undergo PEF and finally MCT testing. This strategy dominated other strategies that did not utilise MCT, producing higher health outcomes at a lower cost to the health service. Two strategies that made more individuals undergo MCT were not cost-effective at the threshold with incremental cost-effectiveness ratios of £20,276 and £32,565 per/QALY respectively. Although assumptions were made relating to conditional dependence and the consequences of false diagnoses, the model's results were found to be robust to significant changes in these and other uncertain parameters. cOnclusiOns: These findings highlight the need for thorough objective testing for diagnosing asthma as doing so has the potential to improve health outcomes whilst reducing costs to the health service. Objectives: The determination of coronary calcium score allows to identify individuals for which primary prevention with statins may be unnecessary. In this study it is shown that the presence of risk factors for developing diabetes interacts with the benefits of this identification. MethOds: A Markov model was used to estimate the evolution of two cohorts with elevated C-reactive protein and low LDL cholesterol: one without risk factors for developing diabetes and another with those risk factors. The progression of both cohorts was simulated assuming four alternative strategies: "no treatment", "treat if score> 100", "treat if score> 0" and "treat all". Results: For individuals without risk factors for diabetes, the "treat all" strategy is the most expensive but allows to achieve better clinical outcomes, with a cost per QALY of 24,164€ vs. the strategy "treat if score> 0". For those with risk factors for diabetes, the strategy "treat all" remains the most expensive, but the decrease in coronary events does not compensate the increase in diabetes incidence, whereby the strategy "treat all" is dominated by "treat if score> 0". The cost per QALY of this latter strategy in comparison to "treat if score> 100" is 36,034€ . Deterministic and probabilistic sensitivity analysis show that results are robust. cOnclusiOns: The presence of risk factors for diabetes affects the cost-effectiveness of using coronary calcium score as a guide to implement primary prevention in this population.
PMD98 exaMining tHe eConoMiC iMPaCt of laBoratory DeveloPeD testing in floW CytoMetry iMMUnoPHenotyPing for HeMatologiC MalignanCies: an analysis of HealtH resoUrCe Utilization
Smallwood C 1 , Galama L 1 , Apoll L 1 , Heinrich K 2 , Buchanan S 3 , Demers J 3 1 Becton, Dickinson and Company, Mississauga, ON, Canada, 2 Becton, Dickinson and Company, Franklin Lakes, NJ, USA, 3 St. Michael's Hospital, Toronto, ON, Canada Objectives: Each year approximately 900,000 new cases of hematological malignancies are diagnosed globally. Diagnosis is comprised of multiple modalities, including flow cytometry. Current laboratory developed testing (LDT) for flow cytometry is non-standardized and error prone. Insufficient research has been published evaluating the cost and errors in this space. Manual work, including steps such as antibody selection, compensation, and pipetting have been identified as potential sources of error in flow cytometry. The aim of this study is to quantify the time and associated economic impact of manual work in a flow cytometry process for hematological malignancies. MethOds: An observational study was conducted at a public Canadian acute care clinical laboratory in collaboration with a lean specialist team for the purposes of workflow analysis. The results of this pilot were used to inform this extended costing analysis. Evaluation of the instrument, reagent, and sample preparation was performed. Total opportunities for error in the workflow were identified (defined as steps involving manual efforts) and manual labor time was then used to estimate indirect costs. Results: A total of 37 steps were involved in instrument set-up, 81 steps for manual reagent and sample preparation, each of these steps containing multiple opportunities for error. At a 550 bed institution performing 591 leukemia and lymphoma tests annually, it was estimated that a total of 365 hours of manual labor by a skilled medical lab technologist incurred indirect costs of $18,250. cOnclusiOns: Based on this case study, manual work resulted in substantial cost to the laboratory in indirect costs. This suggests that in addition to reducing the potential for error, minimizing unnecessary manual steps in the flow cytometry workflow could also reduce laboratory indirect costs and improve efficiency. Future research is warranted to quantify the frequency of errors in manual steps in LDT for flow cytometry.
PMD99 eConoMiCal anD organizational iMPaCt of aDoPting Different in sitU HyBriDization teCHnologies to assess Her2 gene aMPlifiCation in Breast CanCer
Paolini D 1 , Rossoni R 1 , Guardione D 1 , Arena V 2 1 Roche Diagnostics S.p.A., Monza, Italy, 2 Policlinico Universitario, Rome, Italy Objectives: Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing. MethOds: We conducted an analysis to evaluate costs, times (laboratory personnel working hours) and laboratory-space to process a sample using the manual method (FISH) compared to the automated system (SISH). The analysis was performed from the pathology laboratory's perspective. We analysed the complete workflow (laboratory personnel and medical resource used) to perform the two tests (FISH and SISH) during pathol-
PMD94 DelayeD enHanCeMent CarDiaC MagnetiC resonanCe to refine Patient seleCtion for iMPlantaBle CarDioverter DefiBrillator tHeraPy in PriMary Prevention -an exPloratory Cost-effeCtiveness analysis
Silva Miguel L 1 , Ferreira AM 2 1 CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 2 Hospital de Santa Cruz and Hospital da Luz, Carnaxide and Lisbon, Portugal Objectives: The majority of patients who get an implantable cardioverter defibrillator (ICD) for primary prevention of sudden cardiac death (SCD) never need to receive appropriate ICD therapies. Better risk-stratifying tools are thus needed to improve the cost-effectiveness of device implantation. The purpose of this study was to assess the cost-effectiveness of using delayed enhancement cardiac magnetic resonance (CMR) to refine patient selection for ICD therapy in primary prevention. MethOds: A Markov model was developed to assess long-term survival, quality-adjusted life years (QALYs), and lifetime costs for a cohort of patients with reduced left ventricular ejection fraction without previous ventricular arrhythmias. Two different strategies were compared: A) implant an ICD in all patients ("ICD for all"); and B) perform CMR and implant an ICD only in patients with delayed enhancement exceeding 5% of myocardial mass ("CMR-guided ICD"). Clinical and economic inputs were derived from European representative literature. Results: The "ICD for all" strategy led to a total cost of 68,818€ and 7.0 QALY per patient, implying an incremental cost of 7,372€ and allowing a gain of 0.1 QALY when compared to the strategy "CMR-guided ICD". Consequently, the cost-utility ratio is 77,943€ per QALY. Probabilistic sensitivity analysis showed that, assuming a willingness to pay of 50,000€ per QALY, the "ICD for all" strategy would be cost-effective in 31 % of the simulations. cOnclusiOns: Results suggest that implanting ICD in selected patients allows to use this device in those that benefit most, improving the cost-effectiveness of ICD implantation for the primary prevention of sudden cardiac death. Objectives: Mutations in BRCA1 and BRCA2 genes are associated with an increased risk of breast and ovarian cancer. If a BRCA mutation is detected in women with ovarian cancer their unaffected relatives may be offered genetic testing and prophylactic surgery. The long-term cost-effectiveness of providing BRCA testing to women with ovarian cancer and to their unaffected female first-degree relatives in the UK has previously been evaluated using a lifetime Markov model, but the approach had a number of limitations. The current study will employ a hybrid discrete event simulation (DES) structure that addresses some of the Markovian limitations associated with the previous model and will differentiate between BRCA1 and BRCA2 mutations and will consider results for a number of possible UK family pedigrees. MethOds: A hybrid DES will be constructed with a lifetime horizon, to evaluate the cost-effectiveness of BRCA testing in women with ovarian cancer and their female first-and second-degree relatives versus no testing. The model will consider the incidence of ovarian and breast cancer, differentiating between those with BRCA1 and BRCA2 mutations, as well as the associated mortality rates. Individuals identified as BRCA1 or BRCA2 positive will be eligible to undergo bilateral mastectomy and bilateral salpingo-oophorectomy, which significantly reduce the risk of both ovarian and breast cancer. Results: Results will be presented as an incremental cost-effectiveness ratio expressed as a cost per quality adjusted life year (QALY). These will be compared to the UK cost-effectiveness threshold of £20,000 per QALY gained. A number of sensitivity and subgroup analyses will be presented alongside the base case. cOnclusiOns: We aim to demonstrate that screening patients with ovarian cancer and their first-and second-degree relatives for the BRCA1 and BRCA2 mutation is cost-effective and reduces the incidence of breast and ovarian cancer in the population.
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Cost-effeCtiveness analysis of testing for BrCa1 anD BrCa2 MUtations in WoMen DiagnoseD WitH ovarian CanCer anD tHeir feMale first-anD seConD Degree relatives Using a DisCrete event siMUlation: a Uk HealtH serviCe PersPeCtive
PMD96 iDentifying tHe Most Cost-effeCtive Way of Diagnosing astHMa in aDUlts Using MUltiPle tests -a Cost-Utility analysis froM tHe niCe astHMa gUiDeline
Haines A 1 , Davies E 1 , Higgins B 2 , Menzies-Gow A 3 , Thomas M 4 , Masoli M 5 , Gaillard E 6 1 National Clinical Guideline Centre, London, UK, 2 Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, 3 Royal Brompton and Harefield NHS Foundation Trust, London, UK, 4 University of Southampton, Southampton, UK, 5 Plymouth Hospitals NHS Trust, Plymouth, UK, 6 University of Leicester, Leicester, UK Objectives: To develop an economic model to inform recommendations on the optimal diagnostic pathway for the recent clinical guideline on the diagnosis and monitoring of asthma, commissioned by the National Institute for Health and Care Excellence (NICE). MethOds: A de-novo economic model evaluated current practice alongside six diagnostic pathways comprising of the following tests: spirometry, bronchodilator reversibility (BDR), peak expiratory flow (PEF), fractional exhaled nitric oxide (FeNO) and methacholine/histamine challenge testing (MCT). A model was developed using a decision tree to identify what proportion of individuals would receive a correct (true positive, true negative) or incorrect (false positive, false negative) diagnosis, utilising diagnostic accuracy data in adults from systematic reviews conducted for each test. These proportions fed into one of four Markov models, depending on the diagnosis, which calculated final health and cost outcomes. The model explored the impact of alternative false diagnoses, such as chronic obstructive pulmonary disease, and applied modelling techniques to account for the effect of conditional dependence on diagnostic accuracies. Results: The most cost-effective strategy at a £20,000 per/QALY threshold consisted of all individuals undergoing
